Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Under normal circumstances, the study of health problems after COVID vaccinations posted online on Feb. 25 might not have generated much controversy.Its principal authors were well-respected ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

The next-generation cost needs to be added to the long-term effects on vaccinees. Yet, Dr. Hatfill writes, the American College of Obstetrics and Gynecology (ACOG) has continued to promote the mass ...

The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...

Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...